Clinical trials
catalyst calendar across sponsors →Studies where ANTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 1 observational · 1 with posted results
Held by 5 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, Balyasny Asset Management L.P., RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 14.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| First-in-Human Trial of Oral AN2-502998NCT07024589Evaluate the Incidence of Treatment Emergent Adverse Events at Baseline and Through Study Completion for a Single DoseRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: AN2-502998, Placebo | Healthy Volunteers | 72 | 2026-03-14actual | 2026-04-30 |
| Study of Epetraborole in Patients With Treatment-refractory MAC Lung DiseaseNCT05327803results2026-06-10Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of EpetraboroleRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study. | Drug: Epetraborole, Placebo | MAC Lung Disease, Treatment Refractory MAC Lung Disease | 177 | 2024-12-18actual | 2026-06-10 |
| An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed MelioidosisNCT06089668observationalData Collection of patients in Thailand with "suspected melioidosis" | — | Completed | Other: Observational Study | Melioidosis | 200 | 2024-10-31actual | 2025-05-31 |
| A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult SubjectsNCT05995444Changes to QTc intervalRandomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: Epetraborole and matching placebo, Epetraborole, Placebo, Moxifloxacin | Healthy Volunteers | 24 | 2023-07-26actual | 2023-12-21 |
| A Study of Epetraborole Tablets in Subjects With Degrees of Renal FunctionNCT05283746Characterize the PK Profile of Epetraborole and M3: Maximum Plasma ConcentrationOpen-label · Other | Phase 1 | Completed | Drug: Epetraborole | Renal Insufficiency | 40 | 2022-06-10actual | 2022-07-15 |
| Phase 1 Study of Epetraborole TabletsNCT04892641Evaluate the Incidence of Treatment Emergent Adverse Events at Baseline and Through Study CompletionRandomized · Quadruple-masked · Other | Phase 1 | Completed | Drug: Epetraborole, Placebo | Healthy Volunteers | 51 | 2022-02-26actual | 2024-03-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19